STOCK TITAN

Exicure (XCUR) Stock News, Nov 12, 2020

XCUR NASDAQ

Exicure, Inc. develops clinical-stage biotechnology programs for hematologic diseases, led by burixafor (GPC-100), a highly selective small-molecule CXCR4 antagonist. Company updates center on burixafor's role in hematopoietic stem cell mobilization for multiple myeloma transplant settings, sickle cell disease, cell and gene therapy support, and acute myeloid leukemia chemosensitization.

Recurring news also covers clinical data presentations and publications, collaborations for combination approaches, financial results, liquidity disclosures, and research spending following Exicure's acquisition of GPCR Therapeutics USA. Earlier company context includes its historical focus on nucleic acid therapies and restructuring before the current hematology-focused pipeline.

Rhea-AI Summary

Exicure, Inc. (NYSE American:XCUR) will present at the virtual Fall Investor Summit from November 16-18, 2020. This event includes 75 companies and over 300 institutional and retail investors. Exicure focuses on developing nucleic acid-based therapeutics for rare genetic diseases and cancer. Their proprietary spherical nucleic acid (SNA) technology aims to improve drug efficacy across various cells and tissues. The conference connects smallcap and microcap companies with qualified investors, offering a platform for valuable networking.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.28%
Tags
conferences

FAQ

What is the current stock price of Exicure (XCUR)?

Exicure (XCUR) last closed at $1.08.

What is the market cap of Exicure (XCUR)?

The market cap of Exicure (XCUR) is approximately $7.1M.